Marketed in Spain the first medication derived from cannabis to treat refractory epilepsy
From September 2021, Cannabidiol (CBD) will be marketed in Spain as the first medication used to treat refractory epilepsy, which does not respond we1
From September 2021, Cannabidiol (CBD) will be marketed in Spain as the first medication used to treat refractory epilepsy, which does not respond we1
Cardiology, cardiac surgery, orthopaedic surgery and traumatology, gastroenterology, endocrinology and nutrition, neurology and medical oncology are1
This methodology makes it possible to determine the risk of developing these diseases before symptoms appear in people with REM sleep behavior disord1
Approximately a quarter, 25.8%, of patients had seizures more frequently than before lockdown. Half felt more anxious or depressed than us1
The Hospital Clínic de Barcelona’s Multiple Sclerosis and Neuroimmunology Department has conducted a study to ascertain the impact of COVID-19 on Mul1
Stroke is a very common disease that continues to be the second highest cause of death in the world, and the top cause of permanent disability. Altho1
Researchers from the Institute of Neurosciences of the University of Barcelona (UBNeuro), Hospital Clínic and the IDIBAPS have identified a group of1
Recent studies show that high pollution in the environment increases the risk of having a stroke According to the Spanish Society of Neurology (in S1